健友股份(603707.SH)：子公司获得美国FDA醋酸奥曲肽注射液药品增加生产场地注册批件

Core Viewpoint - The company Meitheal Pharmaceuticals, Inc., a subsidiary of Jianyou Co., Ltd. (603707.SH), has received approval from the U.S. FDA to increase production capacity for its Acetate Octreotide Injection at its Nanjing facility, which is significant for treating various medical conditions [1]. Group 1 - Meitheal Pharmaceuticals has been granted approval for Acetate Octreotide Injection in three concentrations: 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL [1]. - The approved indications for the drug include treatment for acromegaly, severe diarrhea associated with metastatic carcinoid syndrome, flushing episodes, and diarrhea related to vasoactive intestinal peptide-secreting tumors [1].